The Oncology Institute, Inc. TOI Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s amortization expense related to capitalized debt issuance costs?
- The Oncology Institute, Inc. (TOI) reported amortization expense related to capitalized debt issuance costs of $1.21M in Q1 2026.
- How has The Oncology Institute, Inc.'s amortization expense related to capitalized debt issuance costs changed year-over-year?
- The Oncology Institute, Inc.'s amortization expense related to capitalized debt issuance costs decreased by 75.2% year-over-year, from $4.87M to $1.21M.
- What is the long-term trend for The Oncology Institute, Inc.'s amortization expense related to capitalized debt issuance costs?
- Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s amortization expense related to capitalized debt issuance costs has grown at a 254.6% compound annual growth rate (CAGR), from $53K to $8.38M.